Press Releases

Date Title  
Toggle Summary Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
- Significant improvements in neuromuscular function as assessed by the CHOP-INTEND scale - Significant improvements in respiratory function as assessed by maximal inspiratory pressure (MIP) - Multiple developmental milestones achieved at 12 weeks in first treated patient SAN FRANCISCO , Jan.
Toggle Summary Audentes Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO , Jan. 3, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.